101 related articles for article (PubMed ID: 15760554)
1. [The prognostic value of cellular immunity function in patients with hepatocellular carcinoma].
Kong L; Yao SK; Liu JX; Wang N
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):194-7. PubMed ID: 15760554
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of CD8(+) and CD8(+)CD28(-) cell subsets in patients with hepatocellular carcinoma].
Qiu YR; Yang CL; Chen LB; Wang Q
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jan; 22(1):72-3. PubMed ID: 12390853
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
Zhang Q; Yang L; Liu S; Zhang M; Jin Z
Front Immunol; 2021; 12():645835. PubMed ID: 34177894
[TBL] [Abstract][Full Text] [Related]
4. CD8
Nandi M; Pal S; Ghosh S; Chakraborty BC; Dey D; Baidya A; Shil A; Chattopadhyaya S; Banerjee S; Santra A; Chowdhury A; Datta S
Clin Sci (Lond); 2019 Sep; 133(17):1917-1934. PubMed ID: 31477625
[TBL] [Abstract][Full Text] [Related]
5. Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma.
Cao ZX; Chen XP; Wu ZD
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):562-5. PubMed ID: 14627520
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.
Attallah AM; Tabll AA; El-Sadany M; Ibrahim TA; El-Dosoky I
Clin Exp Med; 2003 Nov; 3(3):181-5. PubMed ID: 14648234
[TBL] [Abstract][Full Text] [Related]
7. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma.
Lu W; Li YH; He XF; Chen Y; Zeng QL; Qiu YR
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jun; 22(6):524-6. PubMed ID: 12297475
[TBL] [Abstract][Full Text] [Related]
8. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
9. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.
Huang Y; Wang F; Wang Y; Zhu Z; Gao Y; Ma Z; Xu R; Du Z
J Gastroenterol Hepatol; 2014 Apr; 29(4):851-9. PubMed ID: 24303990
[TBL] [Abstract][Full Text] [Related]
10. Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma.
Yuen MF; Hughes RD; Heneghan MA; Langley PG; Norris S
Cancer; 2001 Oct; 92(8):2136-41. PubMed ID: 11596030
[TBL] [Abstract][Full Text] [Related]
11. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma.
Wang F; Jing X; Li G; Wang T; Yang B; Zhu Z; Gao Y; Zhang Q; Yang Y; Wang Y; Wang P; Du Z
Liver Int; 2012 Apr; 32(4):644-55. PubMed ID: 22118340
[TBL] [Abstract][Full Text] [Related]
12. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma.
Shi J; Wang Y; Wang F; Zhu Z; Gao Y; Zhang Q; Du Z
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):855-864. PubMed ID: 32205116
[TBL] [Abstract][Full Text] [Related]
14. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size.
Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Mandeli J; Hiotis SP
J Immunother; 2016 Jan; 39(1):36-44. PubMed ID: 26641260
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-35 Dampens CD8
Yang L; Shao X; Jia S; Zhang Q; Jin Z
Front Immunol; 2019; 10():1032. PubMed ID: 31134088
[TBL] [Abstract][Full Text] [Related]
17. [Arginine supplementation in total parenteral nutrition improves postoperative cellular immune function of patients with hepatocellular carcinoma after operation].
Zhou ZX; Zhang LJ; Huang XH; Kong QY; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1094-6. PubMed ID: 17666360
[TBL] [Abstract][Full Text] [Related]
18. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
19. Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression.
Zhu J; Feng A; Sun J; Jiang Z; Zhang G; Wang K; Hu S; Qu X
J Gastroenterol Hepatol; 2011 Oct; 26(10):1519-26. PubMed ID: 21557772
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
